A booster dose of vaccine reduces risk of COVID infection by 95%. Given the number of unvaccinated people, & the number or vulnerable vaccinated people, reducing infections to this degree is a big deal.
1/
Reducing infections reduces risk of deaths from Covid, morbidity from acute Covid, risk of long covid, risk of transmission to others, and the rise of mutants.
2/
The big question we grapple with now is not whether boosters work. (They do). It is the more difficult question of how boosters here will affect vaccine supply around the world.
3/
A huge proportion of the population in low income countries has not received even one dose. Providing vaccines to them is not only the right thing to do but will also help us by reducing risk of new vaccine resistant variants.
4/
The question is can we do both? Provide boosters and help the world. Yes. I think so. If Moderna, Pfizer help by transferring technology to manufacture vaccines we can do both.
We need to continue pressure these companies to not just donate doses but transfer tech.
The data on the efficacy of booster dose is in this thread.
Efficacy retained in key subgroups irrespective of age, sex, race, ethnicity, or comorbid conditions.
Note when a booster dose has 96% efficacy compared to those who had 2 doses of Pfizer, then you can figure out that vaccine efficacy between no vaccine versus 3 doses is >99%.
UK COVID cases surging compared to EU. But vaccination is protecting against deaths. See disconnect.
You can see the same disconnect between cases and deaths comparing UK to individual countries.
But the effect of high cases is that although deaths are much lower than what they would have been without vaccination, since vaccines are not perfect there will be some increase in hospitalizations and deaths.
And when you look closely, this is indeed happening in the UK.
IQVIA report: Good news is drug spending as % of healthcare spending is stable at ~15%.
Worrisome: While $ spent on cholesterol, antibiotics, & ulcer meds is lower, the ones rising are ones that will continue go up: oncology, immunology, diabetes. iqvia.com/Insights/The-I…
That's because cholesterol drugs and peptic ulcer drugs work chronically. Not just a few months and stop. So when you have a lot of generics, prices go down due to competition.
In contrast, oncology, immunology drugs are either ones that don't work for very long or are biologics
So there will continue to be newer and more expensive drugs each year and we are not seeing that effect yet. Every new cancer drug sold since 2017 has been >$100,000 per year. And that opening price has kept going up. These drugs also work only for a few months on average.
Lesson for all of us: There is waning immunity after two doses of vaccination, especially in the elderly. This is why boosters are recommended. The risk of transmission is still there which is why for now masks and other preventive measures are recommended.
I'm not a virologist or vaccinologist. I'm addressing this issue as someone whose career has been focused on plasma cells, the cells that make antibodies, for over 20 years. 👇
1) When first exposed to an antigen, virus or vaccine, the immune system produces a primary immune response. On exposure to same antigen again, it produces a better, bigger, and more durable secondary response. Basic immunology. microbiologynotes.com/differences-be…
Sometimes the first infection gives a long enough exposure to the antigen to stimulate the secondary response. Sometimes it's not. Depends on the virus and duration of infection.